Product Description
AstraZeneca is developing TACE (transarterial chemoembolization) as a transarterial therapy procedure for the treatment of hepatocellular carcinoma (HCC). (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03778957)
Mechanisms of Action: ER Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Injection
FDA Designation: None *
Approval Status: Approved
Approved Countries: Brazil | Chile | Colombia | Dominican Republic | Ecuador | India | Ireland | Ukraine
Approved Indications: None
Known Adverse Events: None
Company: Zhejiang University
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Denmark, Egypt, France, Germany, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Malaysia, Mexico, Netherlands, New Zealand, Norway, Philippines, Portugal, Puerto Rico, Russia, Saudi Arabia, Singapore, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Vietnam
Active Clinical Trial Count: 26
Highest Development Phases
Phase 3: Hepatocellular Carcinoma|Melanoma|Neuroendocrine Tumors|Primitive Neuroectodermal Tumors
Phase 2: Cholangiocarcinoma|Liver Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| JapicCTI-205286 | P3 |
Active |
Hepatocellular Carcinoma |
2029-12-31 |
|
| ML42612 | P3 |
Active, not recruiting |
Hepatocellular Carcinoma |
2029-02-28 |
35% |
| ML42612 | P3 |
Active, not recruiting |
Hepatocellular Carcinoma |
2029-02-28 |
35% |
| LEAP-012 | P3 |
Active, not recruiting |
Hepatocellular Carcinoma |
2028-06-30 |
44% |
| 23-OBU-FJ-HCC-II-012 | P2 |
Recruiting |
Hepatocellular Carcinoma |
2026-11-15 |